Compare AbbVie Inc (ABBV) vs SkyWest Inc (SKYW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs SkyWest Inc — how do they compare? AbbVie Inc trades at $252.5 (market cap $449.91B), while SkyWest Inc trades at $96.89 (market cap $3.88B). The key difference: AbbVie Inc is far larger — about 116× SkyWest Inc's market cap, and AbbVie Inc pays a 2.72% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| ABBV | SKYW | |
|---|---|---|
Market Cap | $449.91B | $3.88B |
Sector | Health | Technology |
52-Week High | $261.07 | $123.72 |
52-Week Low | $184.85 | $78.40 |
Enterprise Value | $513.38B | $5.73B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
SkyWest (SKYW) trades at $98.75, up 1.93% with a bullish technical signal supported by moving averages. The stock shows attractive valuation with P/E of 9.47 and P/S of 0.99, while maintaining strong profitability with 10.42% net margin and 16.5% ROE. Recent earnings beat expectations in Q1 2026, and the company maintains stable revenue around $4.1B with consistent cash flow generation from operations exceeding $900M annually.
The outlook remains positive with 56% analyst buy ratings and $109.33 consensus price target suggesting 11% upside. Key risks include rising fuel costs impacting airline profitability and negative net cash flow trends. The upcoming Q2 2026 earnings call on July 23 will be crucial for confirming growth trajectory amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
